TABLE 2.

Comparison of properties of mDC derived from study subjects with those of mDC derived from a cohort of normal donors

Subjects (n)Mean (range)
YieldViability (%)Purity (%)IL-12 (pg/ml)b
Study participants (18)9.1 × 107 (1.3 × 107-2.7 × 108)93 (69-99)100 (47a-100)347.7 (11-1,605)c
Uninfected volunteers (5)2.5 × 108 (2.3 × 108-3.5 × 108)90 (85-95)77 (75-89)270.0 (8-999)d
  • a In one subject, a second plastic adherence was required to increase purity as defined by positivity for CD86.

  • b IL-12 production levels in DC supernatants were measured as described in Materials and Methods.

  • c n = 15: three subjects had insufficient mature DC at the time of scheduled vaccination to permit IL-12 testing.

  • d n = 1.